U.S. market Open. Closes in 12 minutes

LYRA | Lyra Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Revenue1.56M1.36M285.00KN/AN/A1.24M
Cost of Revenue278.00K1.07M1.00M95.00K27.00KN/A
Gross Profit1.28M296.00K-716.00K-95.00K-27.00K1.24M
Operating Expenses66.81M56.35M43.90M22.21M16.52M8.50M
Selling, General & Admin19.06M17.56M14.21M9.69M4.49M3.53M
Research & Development47.75M38.80M29.69M12.52M12.03M4.97M
Other Operating Expenses1.59M1.32MN/AN/AN/A1.19M
Operating Income-65.53M-56.31M-43.62M-22.21M-16.52M-7.26M
Other Expenses / Income2.91M1.04M102.00K82.00K213.00K1.19M
Before Tax Income-62.62M-55.27M-43.51M-22.13M-16.31M-6.03M
Income Tax Expenses59.00K13.00K-1.10M-82.00K-213.00K-1.23M
Net Income-62.68M-55.28M-42.41M-22.05M-16.09M-6.03M
Interest ExpensesN/A524.00KN/AN/AN/AN/A
Basic Shares Outstanding49.80M30.24M12.99M8.59M12.92M6.27M
Diluted Shares Outstanding49.80M30.24M12.99M8.59M12.92M6.27M
EBITDA-65.25M-53.67M-43.62M-22.11M-16.49M-7.18M
EBITDA Margin-4,188.06%-3,937.93%-15,303.51%0.00%0.00%-576.93%
EBIT-62.62M-54.74M-43.51M-22.13M-16.31M-7.26M
EBIT Margin-4,019.32%-4,016.21%-15,267.72%0.00%0.00%-583.52%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙